



ATTORNEY'S DOCKET NO. 10277/7007(HCL)

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 0 8 2001

Applicant(s): Serial No.:

Newell et al.

09/470,494

TECH CENTER 1600/2900

Filed:

December 22, 1999

For:

USE OF CD40 ENGAGEMENT TO ALTER T CELL RECEPTOR USAGE

Examiner:

Phillip Gambel

Art Unit:

1644

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231, on the 2nd day of August, 2001.

Helen C. Lockhart

BOX NON-FEE AMENDMENT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement dated July 3, 2001, Applicants hereby request entry of the following election.

ELECTION

Applicants hereby elect Group I (claims 1-40 and 47-66). The claims of Group I are drawn to methods of inducing TCR rearrangement, methods of promoting T cell maturation, and methods of inducing T cell reactivity with a CD40 binding agent.

The Examiner has also requested that Applicants elect a distinct species of CD40 binding agent, co-stimulatory agent. In response to this request for election of species, Applicants elect a

552121.1